Kyowa Kirin and MEI Pharma Reports P-II (MIRAGE) Study Results of Zandelisib for Indolent B-cell Non-Hodgkin’s Lymphoma in Japan
Shots:
- The P-II (MIRAGE) study evaluating zandelisib (60mg, qd for two 28-day cycles) as monothx. in 61 patients aged 70yrs. with r/r iB-NHL
- The results showed ORR (75.4%) and 24.6% achieved a CR while the results are not mature enough to estimate the final DOR. At a median duration of follow-up of 9.5mos, a discontinuation rate due to TEAEs (14.8%) & the results were consistent with the (TIDAL) study
- The P-I study results showed ORR (100%) & 22.2% achieved CR; patients switched to intermittent dosing for AEs, no dose-limiting toxicities were observed in 1st cycle of therapy, and MTD (not reached). At a median duration of follow-up of 17.5mos., the treatment was well tolerated at 60mg resulting in RP2D in Japanese patients
Ref: Businesswire | Image: Kyowa Kirin
Click here to read the full press release
Tags
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
